Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dyskinesia: later-stage trial registry
1 of 4 indexed Dyskinesia trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Dyskinesia: 4 US clinical trials tracked, 1 recruiting.
Dyskinesia is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Adamas Pharmaceuticals, running 2 of these trials.
Enrollment posture brief
Registry condition dyskinesia
OPEN 1 | RECR 25% | LATE 3 | EARLY 0 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Dyskinesia lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dyskinesia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dyskinesia is recruiting below its size-band peers.
1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Registry and Natural History of Epilepsy-Dyskinesia Syndromes
Boston Children's Hospital
NCT06967727
Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy
Neurocrine Biosciences
NCT05206513
Open-Label Safety Study of ADS-5102 in PD Patients With LID
Adamas Pharmaceuticals
NCT02202551
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Adamas Pharmaceuticals
NCT02274766
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Dyskinesia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dyskinesia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dyskinesia page
4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Dyskinesia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Adamas Pharmaceuticals sponsors the most Dyskinesia trials on record, review their full trial history before evaluating a specific study. See Adamas Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dyskinesia condition card totals 4 registered trials; most-linked intervention ADS-5102; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.